BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37:110. [PMID: 29843754 DOI: 10.1186/s13046-018-0777-4] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Tu X, Zhang X, Liao H, Han S, Jiang W, Zheng Y, Zhao P, Tong Z, Fu Q, Qi Q, Shen J, Zhong L, Pan Y, Fang W. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Support Care Cancer 2020;28:5569-79. [DOI: 10.1007/s00520-020-05478-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
3 Ren H, Li W, Liu X, Li S, Guo H, Wang W, Zhao N. Identification and Validation of an 6-Metabolism-Related Gene Signature and Its Correlation With Immune Checkpoint in Hepatocellular Carcinoma. Front Oncol 2021;11:783934. [PMID: 34869039 DOI: 10.3389/fonc.2021.783934] [Reference Citation Analysis]
4 Liang L, Ge K, Zhang F, Ge Y. The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. Cell Mol Biol Lett 2018;23:58. [PMID: 30564277 DOI: 10.1186/s11658-018-0122-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wei Y, Wang Y, Liu N, Qi R, Xu Y, Li K, Feng Y, Shi B. A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Front Pharmacol 2022;12:820446. [DOI: 10.3389/fphar.2021.820446] [Reference Citation Analysis]
6 Qiu L, Ning H, Zhu Y, Yang Q, Liu L, Luo L, Gao Y, Xing Y. Feedback regulation of antioxidant transcription factor NFE2L1 and immunostimulatory factor 41BBL mediates the crosstalk between oxidative stress and tumor immunity. Mol Immunol 2021;141:265-72. [PMID: 34902807 DOI: 10.1016/j.molimm.2021.12.001] [Reference Citation Analysis]
7 Sun W, Lv S, Li H, Cui W, Wang L. Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. Genes (Basel) 2018;9:E633. [PMID: 30558227 DOI: 10.3390/genes9120633] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
8 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
9 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Reference Citation Analysis]
10 Zhu J, Tang B, Gao Y, Xu S, Tu J, Wang Y, Yang W, Fang S, Weng Q, Zhao Z, Xu M, Yang Y, Chen M, Lu C, Ji J. Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2. J Inflamm Res 2021;14:4089-109. [PMID: 34466015 DOI: 10.2147/JIR.S315957] [Reference Citation Analysis]
11 Ma J, Han W, Lu K. Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-Environment. Front Oncol 2021;11:711756. [PMID: 34490109 DOI: 10.3389/fonc.2021.711756] [Reference Citation Analysis]
12 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 De Keukeleire SJ, Vermassen T, Nezhad ZM, Kerre T, Kruse V, Vlierberghe HV, Vermaelen K, Rottey S. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk? Immunotherapy 2021;13:409-18. [PMID: 33487052 DOI: 10.2217/imt-2020-0273] [Reference Citation Analysis]
14 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
15 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Reference Citation Analysis]
16 Fang X, Guo Z, Liang J, Wen J, Liu Y, Guan X, Li H. Neoantigens and their potential applications in tumor immunotherapy. Oncol Lett 2022;23:88. [PMID: 35126730 DOI: 10.3892/ol.2022.13208] [Reference Citation Analysis]
17 Peng JB, Peng YT, Lin P, Wan D, Qin H, Li X, Wang XR, He Y, Yang H. Differentiating infected focal liver lesions from malignant mimickers: value of ultrasound-based radiomics. Clin Radiol 2021:S0009-9260(21)00486-4. [PMID: 34753587 DOI: 10.1016/j.crad.2021.10.009] [Reference Citation Analysis]
18 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
19 Wang Y, Li N, Tian D, Zhou CW, Wang YH, Yang C, Zeng MS. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:6451-71. [PMID: 34429653 DOI: 10.2147/CMAR.S322179] [Reference Citation Analysis]
20 Zhu HX, Lu WJ, Zhu WP, Yu S. Comprehensive analysis of N6 -methyladenosine-related long non-coding RNAs for prognosis prediction in liver hepatocellular carcinoma. J Clin Lab Anal 2021;:e24071. [PMID: 34741346 DOI: 10.1002/jcla.24071] [Reference Citation Analysis]
21 Sun G, Sun K, Shen C. Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients. World J Surg Oncol 2021;19:137. [PMID: 33941198 DOI: 10.1186/s12957-021-02246-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Maghrouni A, Givari M, Jalili-Nik M, Mollazadeh H, Bibak B, Sadeghi MM, Afshari AR, Johnston TP, Sahebkar A. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. Int Immunopharmacol 2021;93:107403. [PMID: 33581502 DOI: 10.1016/j.intimp.2021.107403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Deng Z, Teng YJ, Zhou Q, Ouyang ZG, Hu YX, Long HP, Hu MJ, Mei S, Lin FX, Dai XJ, Zhang BY, Feng T, Tian XF. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(11): 1725-1740 [PMID: 34853646 DOI: 10.4251/wjgo.v13.i11.1725] [Reference Citation Analysis]
24 Liao J, Zeng D, Li J, Hua Q, Xiao Z, He C, Mao K, Zhu L, Chu Y, Wen W, Zheng L, Wu Y. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int 2020;14:80-95. [DOI: 10.1007/s12072-019-10003-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
25 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Reference Citation Analysis]
26 Tao L, Wang S, Kang G, Jiang S, Yin W, Zong L, Li J, Wang X. PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma. Oncoimmunology 2021;10:2002068. [PMID: 34777920 DOI: 10.1080/2162402X.2021.2002068] [Reference Citation Analysis]
27 Liu W, Ji Z, Wu B, Huang S, Chen Q, Chen X, Wei Y, Jiang J. Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. FEBS Lett 2021. [PMID: 34328657 DOI: 10.1002/1873-3468.14169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Zhang L, Hu S, Chen J, Ma S, Liu F, Liu C, Gao Y. Comprehensive analysis of the MIR4435-2HG/miR-1-3p/MMP9/miR-29-3p/DUXAP8 ceRNA network axis in hepatocellular carcinoma. Discov Onc 2021;12. [DOI: 10.1007/s12672-021-00436-3] [Reference Citation Analysis]
29 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Reference Citation Analysis]
30 Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res 2019;38:87. [PMID: 30777100 DOI: 10.1186/s13046-019-1085-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 23.7] [Reference Citation Analysis]
31 Fu R, Yu F, Wu W, Liu J, Li J, Guo F, Xu L, Wang F, Cui X. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. Int Immunopharmacol 2021;101:108195. [PMID: 34678691 DOI: 10.1016/j.intimp.2021.108195] [Reference Citation Analysis]
32 Xu D, Wang Y, Wu J, Lin S, Chen Y, Zheng J. Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma. Cancer Cell Int 2021;21:621. [PMID: 34819088 DOI: 10.1186/s12935-021-02326-8] [Reference Citation Analysis]
33 Goto T. Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines (Basel) 2019;7:E100. [PMID: 31455032 DOI: 10.3390/vaccines7030100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
34 Ma J, Chen S, Liu Y, Han H, Gong M, Song Y. The role of exosomal miR-181b in the crosstalk between NSCLC cells and tumor-associated macrophages. Genes Genomics 2022. [PMID: 35150402 DOI: 10.1007/s13258-022-01227-y] [Reference Citation Analysis]
35 Ding X, Sun W, Chen J. IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway. Cancer Cell Int 2018;18:176. [PMID: 30459526 DOI: 10.1186/s12935-018-0671-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
36 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
37 Feder S, Haberl EM, Spirk M, Weiss TS, Wiest R, Buechler C. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clin Exp Med 2020;20:289-97. [PMID: 32078718 DOI: 10.1007/s10238-020-00617-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Lawal G, Xiao Y, Rahnemai-Azar AA, Tsilimigras DI, Kuang M, Bakopoulos A, Pawlik TM. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel) 2021;9:1184. [PMID: 34696292 DOI: 10.3390/vaccines9101184] [Reference Citation Analysis]
39 Kim S, Lee M, Song Y, Lee SY, Choi I, Park IS, Kim J, Kim JS, Kim KM, Seo HR. Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma. J Exp Clin Cancer Res 2021;40:127. [PMID: 33838671 DOI: 10.1186/s13046-021-01912-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Su L, Guo W, Lou L, Nie S, Zhang Q, Liu Y, Chang Y, Zhang X, Li Y, Shen H. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma. Mol Carcinog 2020;59:520-32. [PMID: 32134157 DOI: 10.1002/mc.23176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
41 Wang X, Lu J, Guo G, Yu J. Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death Dis 2021;12:299. [PMID: 33741903 DOI: 10.1038/s41419-021-03568-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zhang J, Zhang X, Li J, Song Z. Systematic analysis of the ABC transporter family in hepatocellular carcinoma reveals the importance of ABCB6 in regulating ferroptosis. Life Sci 2020;257:118131. [PMID: 32710948 DOI: 10.1016/j.lfs.2020.118131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Wang M, Xiong Z. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Int J Gen Med 2021;14:6343-58. [PMID: 34629898 DOI: 10.2147/IJGM.S333390] [Reference Citation Analysis]
44 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
45 Liu H, Liao W, Fan L, Zheng Z, Liu D, Zhang QW, Yang A, Liu F. Ethanol extract of Ophiorrhiza pumila suppresses liver cancer cell proliferation and migration. Chin Med 2020;15:11. [PMID: 32021647 DOI: 10.1186/s13020-020-0291-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
46 Guo H, Yang J, Liu S, Qin T, Zhao Q, Hou X, Ren L. Prognostic marker identification based on weighted gene co-expression network analysis and associated in vitro confirmation in gastric cancer. Bioengineered 2021;12:4666-80. [PMID: 34338150 DOI: 10.1080/21655979.2021.1957645] [Reference Citation Analysis]
47 Zhang X, Jiang D, Yang S, Sun Y, Liu Y, Shi J, Hu C, Pan J, Liu T, Jin B, Yang K. BAP31 Promotes Tumor Cell Proliferation by Stabilizing SERPINE2 in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:607906. [PMID: 33363167 DOI: 10.3389/fcell.2020.607906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Criscuolo D, Morra F, Giannella R, Visconti R, Cerrato A, Celetti A. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. J Exp Clin Cancer Res 2019;38:91. [PMID: 30791940 DOI: 10.1186/s13046-019-1089-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
49 Rotte A, D'Orazi G, Bhandaru M. Nobel committee honors tumor immunologists. J Exp Clin Cancer Res 2018;37:262. [PMID: 30376854 DOI: 10.1186/s13046-018-0937-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
50 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Wang X, Wu Y, Wen D, Wu LY, Zhao Y, He Y, Yang H. An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma. Med Sci Monit 2020;26:e921786. [PMID: 32527991 DOI: 10.12659/MSM.921786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep 2020;21:1849-60. [PMID: 32319631 DOI: 10.3892/mmr.2020.10991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
53 Holah NS. The Clinical Value of VDR and CTLA 4 in Evaluating the Prognosis of Invasive Duct Carcinoma of Egyptian Patients and their Benefit as a Target Therapy. Asian Pac J Cancer Prev 2021;22:1183-94. [PMID: 33906311 DOI: 10.31557/APJCP.2021.22.4.1183] [Reference Citation Analysis]
54 Zhao C, Wu X, Chen J, Qian G. The therapeutic effect of IL-21 combined with IFN-γ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma. Journal of Advanced Research 2022;36:89-99. [DOI: 10.1016/j.jare.2021.05.010] [Reference Citation Analysis]
55 Wen B, Zhang C, Zhou J, Zhang Z, Che Q, Cao H, Bai Y, Guo J, Su Z. Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways. Pharmacol Ther 2021;222:107752. [PMID: 33253739 DOI: 10.1016/j.pharmthera.2020.107752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Higuchi R, Goto T, Hirotsu Y, Nakagomi T, Yokoyama Y, Otake S, Amemiya K, Oyama T, Omata M. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. J Clin Med 2019;8:E1833. [PMID: 31683962 DOI: 10.3390/jcm8111833] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
57 Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 31952209 DOI: 10.3390/cancers12010212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
58 Sun L, Lin Y, Wang G, Zhang L, Hu L, Lu Z. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer. Biosci Rep 2021;41:BSR20203115. [PMID: 33439969 DOI: 10.1042/BSR20203115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Hurkmans DP, Verhoeven JGHP, de Leur K, Boer K, Joosse A, Baan CC, von der Thüsen JH, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM, Hesselink DA. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. J Immunother Cancer 2019;7:182. [PMID: 31300068 DOI: 10.1186/s40425-019-0653-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
60 Wang J, Li Y, Zhang C, Chen X, Zhu L, Luo T. Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma. Transl Cancer Res 2021;10:4636-51. [PMID: 35116320 DOI: 10.21037/tcr-21-1145] [Reference Citation Analysis]
61 Shin SH, Park MH, Byeon JJ, Lee BI, Park Y, Kim N, Choi J, Shin YG. Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Pharmaceutics 2018;10:E260. [PMID: 30513962 DOI: 10.3390/pharmaceutics10040260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhou YT, Chen H, Ai M, Li SS, Li BY, Zhao Y, Cai WW, Hou B, Ni LL, Xu F, Qiu LY. Type-1 Na+/H+ exchanger is a prognostic factor and associate with immune infiltration in liver hepatocellular carcinoma. Life Sci 2021;278:119613. [PMID: 34000263 DOI: 10.1016/j.lfs.2021.119613] [Reference Citation Analysis]
63 Liu YT, Tseng TC, Soong RS, Peng CY, Cheng YH, Huang SF, Chuang TH, Kao JH, Huang LR. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment. J Immunother Cancer 2018;6:144. [PMID: 30526672 DOI: 10.1186/s40425-018-0462-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
64 Huang W, Wu X, Xiang S, Qiao M, Cen X, Pan X, Huang X, Zhao Z. Regulatory mechanism of miR-20a-5p expression in Cancer. Cell Death Discov 2022;8:262. [PMID: 35577802 DOI: 10.1038/s41420-022-01005-5] [Reference Citation Analysis]
65 Cacabelos R, Carril JC, Sanmartín A, Cacabelos P. Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics. Pharmacoepigenetics. Elsevier; 2019. pp. 191-424. [DOI: 10.1016/b978-0-12-813939-4.00006-1] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
66 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Muir M, Gopakumar S, Traylor J, Lee S, Rao G. Glioblastoma multiforme: novel therapeutic targets. Expert Opin Ther Targets 2020;24:605-14. [PMID: 32394767 DOI: 10.1080/14728222.2020.1762568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
68 Di Cintio F, Dal Bo M, Baboci L, De Mattia E, Polano M, Toffoli G. The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. Front Neurosci 2020;14:603647. [PMID: 33324155 DOI: 10.3389/fnins.2020.603647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
69 Li J, Zhou J, Kai S, Wang C, Wang D, Jiang J. Network-Based Coexpression Analysis Identifies Functional and Prognostic Long Noncoding RNAs in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1371632. [PMID: 33083449 DOI: 10.1155/2020/1371632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Lv R, Tian Y, Yu Z, Liu C. Clinical efficacy of computed tomography-guided microwave ablation sequential transcatheter arterial chemoembolization under edge calculation for primary liver cancer over 5 cm in diameter. J Supercomput. [DOI: 10.1007/s11227-021-04118-3] [Reference Citation Analysis]
71 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Reference Citation Analysis]
72 Pan Q, Cheng Y, Cheng D. Identification of CD8+ T Cell-Related Genes: Correlations with Immune Phenotypes and Outcomes of Liver Cancer. J Immunol Res 2021;2021:9960905. [PMID: 34124275 DOI: 10.1155/2021/9960905] [Reference Citation Analysis]
73 Schizas D, Mastoraki A, Routsi E, Papapanou M, Tsapralis D, Vassiliu P, Toutouzas K, Felekouras E. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int 2020;19:515-23. [PMID: 32753331 DOI: 10.1016/j.hbpd.2020.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
74 Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188638. [PMID: 34688805 DOI: 10.1016/j.bbcan.2021.188638] [Reference Citation Analysis]
75 Ma X, Luo Y, Zeng F, Su C, Liu X, Li X, Lu J. TGF-β1-Mediated PD-L1 Glycosylation Contributes to Immune Escape via c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma. Front Oncol 2022;12:815437. [DOI: 10.3389/fonc.2022.815437] [Reference Citation Analysis]
76 Du S, Sun L, Wang Y, Zhu W, Gao J, Pei W, Zhang Y. ADAM12 is an independent predictor of poor prognosis in liver cancer. Sci Rep 2022;12:6634. [PMID: 35459884 DOI: 10.1038/s41598-022-10608-y] [Reference Citation Analysis]
77 Wang K, Chen X, Jin C, Mo J, Jiang H, Yi B, Chen X. A novel immune-related genes prognosis biomarker for hepatocellular carcinoma. Aging (Albany NY) 2020;13:675-93. [PMID: 33260154 DOI: 10.18632/aging.202173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Hu X, Zhu H, Chen B, He X, Shen Y, Zhang X, Chen W, Liu X, Xu Y, Xu X. Tubulin Alpha 1b Is Associated with the Immune Cell Infiltration and the Response of HCC Patients to Immunotherapy. Diagnostics 2022;12:858. [DOI: 10.3390/diagnostics12040858] [Reference Citation Analysis]
79 Morra F, Merolla F, Criscuolo D, Insabato L, Giannella R, Ilardi G, Cerrato A, Visconti R, Staibano S, Celetti A. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. J Exp Clin Cancer Res 2019;38:90. [PMID: 30786932 DOI: 10.1186/s13046-019-1087-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
80 Hage C, Hoves S, Ashoff M, Schandl V, Hört S, Rieder N, Heichinger C, Berrera M, Ries CH, Kiessling F, Pöschinger T. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLoS One 2019;14:e0219517. [PMID: 31291357 DOI: 10.1371/journal.pone.0219517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
81 Jiang J, Ding Y, Wu M, Lyu X, Wang H, Chen Y, Wang H, Teng L. Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis. Front Oncol 2020;10:1765. [PMID: 33014868 DOI: 10.3389/fonc.2020.01765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Li E, Lin L, Chen CW, Ou DL. Mouse Models for Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1800. [PMID: 31731753 DOI: 10.3390/cancers11111800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
83 Pu J, Xu Z, Nian J, Fang Q, Yang M, Huang Y, Li W, Ge B, Wang J, Wei H. M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway. Cell Death Discov 2021;7:182. [PMID: 34282135 DOI: 10.1038/s41420-021-00556-3] [Reference Citation Analysis]
84 Chen Y, Xia F, Jiang B, Wang W, Li X. Role of Immune Cell-Specific Hypermethylation Signatures in Classification and Risk Stratification of Breast Cancer. Front Med (Lausanne) 2021;8:674338. [PMID: 34513864 DOI: 10.3389/fmed.2021.674338] [Reference Citation Analysis]
85 Abuduhadeer X, Xu X, Aihesan K, Yilihamu M, Zhao Y, Zhang W. Clinical significance of kallikrein 5 as a novel prognostic biomarker in gastric adenocarcinoma. J Clin Lab Anal 2021;35:e23958. [PMID: 34510543 DOI: 10.1002/jcla.23958] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019;3:456-470. [PMID: 30976737 DOI: 10.1002/hep4.1331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
87 Liu Z, Cheng X, Pang B, Wang S, Liu B, Cao C, Qian R, Liang W, Zhu Y, Li P, Gao Y. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma. Int Immunopharmacol 2022;104:108399. [PMID: 35008004 DOI: 10.1016/j.intimp.2021.108399] [Reference Citation Analysis]
88 Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 16.5] [Reference Citation Analysis]
89 Wu M, Mei F, Liu W, Jiang J. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. Biomed Pharmacother. 2020;121:109637. [PMID: 31810126 DOI: 10.1016/j.biopha.2019.109637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
90 Teng CF, Li TC, Wang T, Wu TH, Wang J, Wu HC, Shyu WC, Su IJ, Jeng LB. Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant. J Hepatocell Carcinoma 2020;7:385-401. [PMID: 33365286 DOI: 10.2147/JHC.S282818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Ma R, Qu X, Che X, Yang B, Li C, Hou K, Guo T, Xiao J, Liu Y. Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer. Onco Targets Ther 2021;14:3517-34. [PMID: 34103942 DOI: 10.2147/OTT.S304297] [Reference Citation Analysis]
92 Yao Z, Dong Y, Wu G, Zhang Q, Yang D, Yu JH, Wang WP. Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images. BMC Cancer. 2018;18:1089. [PMID: 30419849 DOI: 10.1186/s12885-018-5003-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
93 Long S, Li M, Liu J, Yang Y, Li G. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling. Aging (Albany NY) 2020;12:7112-28. [PMID: 32310827 DOI: 10.18632/aging.103065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Zhou S, Xu J, Wang D, Wang Y, Meng L, Cao S. Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/5224434] [Reference Citation Analysis]
95 Hong Z, Lu Y, Ran C, Tang P, Huang J, Yang Y, Duan X, Wu H. The bioactive ingredients in Actinidia chinensis Planch. Inhibit liver cancer by inducing apoptosis. J Ethnopharmacol 2021;281:114553. [PMID: 34428524 DOI: 10.1016/j.jep.2021.114553] [Reference Citation Analysis]
96 Wang S, Zhou D, Xu Z, Song J, Qian X, Lv X, Luan J. Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Curr Drug Targets 2019;20:1180-202. [PMID: 30947670 DOI: 10.2174/1389450120666190402145325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
97 Vasuri F, Nerpiti A, Zagnoni S, Ravaioli M, D'Errico A, Fiorentino M. Pd-ligand 1 is expressed in inflammatory cells but not in neoplastic cells in hepatocellular carcinoma: An immunohistochemical study. Acta Histochem. 2020;122:151468. [PMID: 31767125 DOI: 10.1016/j.acthis.2019.151468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Meng Y, Sun J, Wang X, Ma Y, Kong C, Zhang G, Dou H, Nan N, Shi M, Yu T, Piao H. The biological macromolecule Nocardia rubra cell-wall skeleton as an avenue for cell-based immunotherapy. J Cell Physiol 2019. [PMID: 30697721 DOI: 10.1002/jcp.28182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]